The importance of extracellular matrix for cell function and in vivo likeness

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 286-294

  Hansen, N U B ^a,b   Genovese, F ^a   Leeming, D J ^a   Karsdal, M A ^a,b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biomarkers; Ex vivo; Extracellular matrix; Fibrosis; In vitro; Phenotype

Indexed keywords

CALNEXIN; CALRETICULIN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SHC; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE;

APOPTOSIS; BIOLOGICAL MODEL; CELL ADHESION; CELL FATE; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MICROENVIRONMENT; MONOLAYER CULTURE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; TRANSLATIONAL RESEARCH; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CELL CULTURE; CELL DIFFERENTIATION; CONNECTIVE TISSUE DISEASE; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; LIVER CIRRHOSIS; LUNG FIBROSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYSTEMIC SCLEROSIS;

CARDIOVASCULAR DISEASES; CELL COMMUNICATION; CELL DIFFERENTIATION; CELLS, CULTURED; CONNECTIVE TISSUE DISEASES; CYTOKINES; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; LIVER CIRRHOSIS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 84924787406     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.01.006     Document Type: Review

References (135)

1. Ahmad N.N., Donald-McGinn D.M., Zackai E.H., Knowlton R.G., LaRossa D., DiMascio J., et al. A second mutation in the type II procollagen gene (COL2AI) causing stickler syndrome (arthro-ophthalmopathy) is also a premature termination codon. Am. J. Hum. Genet. 1993, 52(1):39-45.
2. Ala-Kokko L., Baldwin C.T., Moskowitz R.W., Prockop D.J. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(17):6565-6568.
3. Ameye L., Aria D., Jepsen K., Oldberg A., Xu T., Young M.F. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J. 2002, 16(7):673-680.
4. Arias-Salgado E.G., Lizano S., Sarkar S., Brugge J.S., Ginsberg M.H., Shattil S.J. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(23):13298-13302.
5. Arias-Salgado E.G., Lizano S., Shattil S.J., Ginsberg M.H. Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain. J. Biol. Chem. 2005, 280(33):29699-29707.
6. Barascuk N., Veidal S.S., Larsen L., Larsen D.V., Larsen M.R., Wang J., et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 2010, 43(10-11):899-904.
7. Barker D.F., Hostikka S.L., Zhou J., Chow L.T., Oliphant A.R., Gerken S.C., et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990, 248(4960):1224-1227.
8. Bergsten E., Uutela M., Li X., Pietras K., Ostman A., Heldin C.H., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 2001, 3(5):512-516.
9. Bi X., Tong C., Dockendorff A., Bancroft L., Gallagher L., Guzman G., et al. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 2008, 29(7):1435-1440.
10. Bissell D.M., Wang S.S., Jarnagin W.R., Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J. Clin. Invest. 1995, 96(1):447-455.
11. Briggs M.D., Rasmussen I.M., Weber J.L., Yuen J., Reinker K., Garber A.P., et al. Genetic linkage of mild pseudoachondroplasia (PSACH) to markers in the pericentromeric region of chromosome 19. Genomics 1993, 18(3):656-660.
12. Briggs M.D., Wright M.J., Mortier G.R. Multiple Epiphyseal Dysplasia, Dominant 1993.
13. Chakravarti S. Functions of lumican and fibromodulin: lessons from knockout mice. Glycoconj. J. 2002, 19(4-5):287-293.
14. Chang H.Y., Chi J.T., Dudoit S., Bondre C., van de R.M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(20):12877-12882.
15. Chaudhary N.I., Roth G.J., Hilberg F., Muller-Quernheim J., Prasse A., Zissel G., et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 2007, 29(5):976-985.
16. Chen X.D., Shi S., Xu T., Robey P.G., Young M.F. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J. Bone Miner. Res. 2002, 17(2):331-340.
17. Chipev C.C., Simon M. Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFbeta1. BMC Dermatol. 2002, 2:13.
18. Chiquet-Ehrismann R., Tucker R.P. Connective tissues: signalling by tenascins. Int. J. Biochem. Cell Biol. 2004, 36(6):1085-1089.
19. Chiquet-Ehrismann R., Tucker R.P. Tenascins and the importance of adhesion modulation. Cold Spring Harb. Perspect. Biol. 2011, 3(5).
20. Corsi A., Xu T., Chen X.D., Boyde A., Liang J., Mankani M., et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. 2002, 17(7):1180-1189.
21. Czarny-Ratajczak M., Lohiniva J., Rogala P., Kozlowski K., Perala M., Carter L., et al. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. Am. J. Hum. Genet. 2001, 69(5):969-980.
22. Dang N., Murrell D.F. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp. Dermatol. 2008, 17(7):553-568.
23. Danielson K.G., Baribault H., Holmes D.F., Graham H., Kadler K.E., Iozzo R.V. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997, 136(3):729-743.
24. Fernandes R.J., Wilkin D.J., Weis M.A., Wilcox W.R., Cohn D.H., Rimoin D.L., et al. Incorporation of structurally defective type II collagen into cartilage matrix in kniest chondrodysplasia. Arch. Biochem. Biophys. 1998, 355(2):282-290.
25. Fischer H., Taylor N., Allerstorfer S., Grusch M., Sonvilla G., Holzmann K., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2008, 7(10):3408-3419.
26. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010, 123(Pt 24):4195-4200.
27. Friedman S.L., Roll F.J., Boyles J., Arenson D.M., Bissell D.M. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J. Biol. Chem. 1989, 264(18):10756-10762.
28. Friedman S.L., Rockey D.C., McGuire R.F., Maher J.J., Boyles J.K., Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 1992, 15(2):234-243.
29. Fu H.L., Valiathan R.R., Arkwright R., Sohail A., Mihai C., Kumarasiri M., et al. Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J. Biol. Chem. 2013, 288(11):7430-7437.
30. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr. J. 2008, 55(1):23-31.
31. Fukuoka T., Kitami Y., Okura T., Hiwada K. Transcriptional regulation of the platelet-derived growth factor alpha receptor gene via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells. J. Biol. Chem. 1999, 274(36):25576-25582.
32. Gaca M.D., Zhou X., Issa R., Kiriella K., Iredale J.P., Benyon R.C. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol. 2003, 22(3):229-239.
33. Genovese F., Barascuk N., Larsen L., Røssel M.R., Nawrocki A., Li Y., et al. Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis & Tissue Repair 2013, 6(9).
34. Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., Hofstrand P.D., et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J. Biol. Chem. 2001, 276(29):27406-27414.
35. Gill M.R., Oldberg A., Reinholt F.P. Fibromodulin-null murine knee joints display increased incidences of osteoarthritis and alterations in tissue biochemistry. Osteoarthritis Cartilage 2002, 10(10):751-757.
36. Godbout C., Follonier C.L., Smith E.A., Talele N., Chow M.L., Garonna A., et al. The mechanical environment modulates intracellular calcium oscillation activities of myofibroblasts. PLoS ONE 2013, 8(5):e64560.
37. Hayward C., Brock D.J. Fibrillin-1 mutations in Marfan syndrome and other type-1 fibrillinopathies. Hum. Mutat. 1997, 10(6):415-423.
38. Heegaard A.M., Corsi A., Danielsen C.C., Nielsen K.L., Jorgensen H.L., Riminucci M., et al. Biglycan deficiency causes spontaneous aortic dissection and rupture in mice. Circulation 2007, 115(21):2731-2738.
39. Heldin C.H., Eriksson U., Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 2002, 398(2):284-290.
40. Huang X., Yang N., Fiore V.F., Barker T.H., Sun Y., Morris S.W., et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am. J. Respir. Cell Mol. Biol. 2012, 47(3):340-348.
41. Huaux F., Liu T., McGarry B., Ullenbruch M., Phan S.H. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 2003, 170(4):2083-2092.
42. Hughes P.E., az-Gonzalez F., Leong L., Wu C., McDonald J.A., Shattil S.J., et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J. Biol. Chem. 1996, 271(12):6571-6574.
43. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110(6):673-687.
44. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326(5957):1216-1219.
45. Jackson G.C., Mittaz-Crettol L., Taylor J.A., Mortier G.R., Spranger J., Zabel B., et al. Pseudoachondroplasia and multiple epiphyseal dysplasia: a 7-year comprehensive analysis of the known disease genes identify novel and recurrent mutations and provides an accurate assessment of their relative contribution. Hum. Mutat. 2012, 33(1):144-157.
46. Jakob A., Unger S., Arnold R., Grohmann J., Kraus C., Schlensak C., et al. A family with a new elastin gene mutation: broad clinical spectrum, including sudden cardiac death. Cardiol. Young 2011, 21(1):62-65.
47. Jakubzick C., Kunkel S.L., Puri R.K., Hogaboam C.M. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol. Res. 2004, 30(3):339-349.
48. Jepsen K.J., Wu F., Peragallo J.H., Paul J., Roberts L., Ezura Y., et al. A syndrome of joint laxity and impaired tendon integrity in lumican- and fibromodulin-deficient mice. J. Biol. Chem. 2002, 277(38):35532-35540.
49. Jones L.K., O'Sullivan K.M., Semple T., Kuligowski M.P., Fukami K., Ma F.Y., et al. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol. Dial. Transplant. 2009, 24(10):3024-3032.
50. Karsdal M.A., Henriksen K., Leeming D.J., Woodworth T., Vassiliadis E., Bay-Jensen A.C. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?. Clin. Biochem. 2010, 43(10-11):793-804.
51. Karsdal M.A., Nielsen M.J., Sand J.M., Henriksen K., Genovese F., Bay-Jensen A.C., et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev. Technol. 2013, 11(2):70-92.
52. Kielty C.M. Elastic fibres in health and disease. Expert Rev. Mol. Med. 2006, 8(19):1-23.
53. Kirkpatrick C.A., Selleck S.B. Heparan sulfate proteoglycans at a glance. J. Cell Sci. 2007, 120(Pt 11):1829-1832.
54. Kontusaari S., Tromp G., Kuivaniemi H., Romanic A.M., Prockop D.J. A mutation in the gene for type III procollagen (COL3A1) in a family with aortic aneurysms. J. Clin. Invest. 1990, 86(5):1465-1473.
55. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol. Metab. 2008, 19(7):239-245.
56. Lampe A.K., Bushby K.M. Collagen VI related muscle disorders. J. Med. Genet. 2005, 42(9):673-685.
57. LaRochelle W.J., Jeffers M., McDonald W.F., Chillakuru R.A., Giese N.A., Lokker N.A., et al. PDGF-D, a new protease-activated growth factor. Nat. Cell Biol. 2001, 3(5):517-521.
58. Lebleu V.S., Macdonald B., Kalluri R. Structure and function of basement membranes. Exp. Biol. Med. (Maywood) 2007, 232(9):1121-1129.
59. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 2001, 194(6):809-821.
60. Leeming D.J., Larsen D.V., Zhang C., Hi Y., Veidal S.S., Nielsen R.H., et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)-assessment of corresponding epitopes. Clin. Biochem. 2010, 43(15):1249-1256.
61. Leeming D., He Y., Veidal S., Nguyen Q., Larsen D., Koizumi M., et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16(7):616-628.
62. Leeming D.J., Nielsen M.J., Dai Y., Veidal S.S., Vassiliadis E., Zhang C., et al. An Enzyme-linked Immunosorbent serum Assay (ELISA) specific for the 7S domain of Collagen Type IV (PIVNP 7S) - a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol. Res. 2012, 42(5):482-493.
63. Li X., Ponten A., Aase K., Karlsson L., Abramsson A., Uutela M., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2000, 2(5):302-309.
64. Li Z., Dranoff J.A., Chan E.P., Uemura M., Sevigny J., Wells R.G. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007, 46(4):1246-1256.
65. Lindroos P.M., Rice A.B., Wang Y.Z., Bonner J.C. Role of nuclear factor-kappa B and mitogen-activated protein kinase signaling pathways in IL-1 beta-mediated induction of alpha-PDGF receptor expression in rat pulmonary myofibroblasts. J. Immunol. 1998, 161(7):3464-3468.
66. Lindroos P.M., Wang Y.Z., Rice A.B., Bonner J.C. Regulation of PDGFR-alpha in rat pulmonary myofibroblasts by staurosporine. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280(2):L354-L362.
67. Luo B.H., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 2007, 25:619-647.
68. Makitie O., Susic M., Cole W.G. Early-onset metaphyseal chondrodysplasia type Schmid associated with a COL10A1 frame-shift mutation and impaired trimerization of wild-type alpha1(X) protein chains. J. Orthop. Res. 2010, 28(11):1497-1501.
69. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
70. Meldrum K.K., Misseri R., Metcalfe P., Dinarello C.A., Hile K.L., Meldrum D.R. TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292(4):R1456-R1464.
71. Milewicz D.M., Urban Z., Boyd C. Genetic disorders of the elastic fiber system. Matrix Biol. 2000, 19(6):471-480.
72. Miller D.L., Ortega S., Bashayan O., Basch R., Basilico C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol. Cell. Biol. 2000, 20(6):2260-2268.
73. Misseri R., Meldrum D.R., Dinarello C.A., Dagher P., Hile K.L., Rink R.C., et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am. J. Physiol. Renal Physiol. 2005, 288(2):F406-F411.
74. Nesbit M., Nesbit H.K., Bennett J., Andl T., Hsu M.Y., Dejesus E., et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999, 18(47):6469-6476.
75. Nielsen M.J., Nedergaard A.F., Sun S., Veidal S.S., Larsen L., Zheng Q., et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Transl. Res. 2013, 5(3):303-315.
76. O'Brien L.E., Jou T.S., Pollack A.L., Zhang Q., Hansen S.H., Yurchenco P., et al. Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat. Cell Biol. 2001, 3(9):831-838.
77. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001, 2(3). (REVIEWS3005).
78. Palotie A., Vaisanen P., Ott J., Ryhanen L., Elima K., Vikkula M., et al. Predisposition to familial osteoarthrosis linked to type II collagen gene. Lancet 1989, 1(8644):924-927.
79. Paulsson M., Heinegard D. Purification and structural characterization of a cartilage matrix protein. Biochem. J. 1981, 197(2):367-375.
80. Pedersen J.A., Swartz M.A. Mechanobiology in the third dimension. Ann. Biomed. Eng. 2005, 33(11):1469-1490.
81. Pedersen J.A., Lichter S., Swartz M.A. Cells in 3D matrices under interstitial flow: effects of extracellular matrix alignment on cell shear stress and drag forces. J. Biomech. 2010, 43(5):900-905.
82. Pinzani M. Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair 2008, 1(1):1.
83. Pinzani M., Marra F., Carloni V. Signal transduction in hepatic stellate cells. Liver 1998, 18(1):2-13.
84. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 2000, 7(3):165-197.
85. Redente E.F., Keith R.C., Janssen W., Henson P.M., Ortiz L.A., Downey G.P., et al. Tumor necrosis factor-alpha accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am. J. Respir. Cell Mol. Biol. 2014, 50(4):825-837.
86. Richards A.J., Martin S., Nicholls A.C., Harrison J.B., Pope F.M., Burrows N.P. A single base mutation in COL5A2 causes Ehlers-Danlos syndrome type II. J. Med. Genet. 1998, 35(10):846-848.
87. Ries K., Krause P., Solsbacher M., Schwartz P., Unthan-Fechner K., Christ B., et al. Elevated expression of hormone-regulated rat hepatocyte functions in a new serum-free hepatocyte-stromal cell coculture model. In Vitro Cell. Dev. Biol. Anim. 2000, 36(8):502-512.
88. Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012, 8(9):1281-1290.
89. Rozario T., DeSimone D.W. The extracellular matrix in development and morphogenesis: a dynamic view. Dev. Biol. 2010, 341(1):126-140.
90. Ruiz P.A., Jarai G. Discoidin domain receptors regulate the migration of primary human lung fibroblasts through collagen matrices. Fibrogenesis Tissue Repair 2012, 5:3.
91. Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 2003, 28(2):105-112.
92. Sauvant P., Sapin V., Abergel A., Schmidt C.K., Blanchon L., exandre-Gouabau M.C. PAV-1, a new rat hepatic stellate cell line converts retinol into retinoic acid, a process altered by ethanol. Int. J. Biochem. Cell Biol. 2002, 34(8):1017-1029.
93. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J. Am. Soc. Nephrol. 2011, 22(7):1200-1207.
94. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115(8):2223-2233.
95. Schaefer L., Tsalastra W., Babelova A., Baliova M., Minnerup J., Sorokin L., et al. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am. J. Pathol. 2007, 170(1):301-315.
96. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 1995, 11:549-599.
97. Schwarzbauer J.E., DeSimone D.W. Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harb. Perspect. Biol. 2011, 3(7).
98. Shute J. Glycosaminoglycan and chemokine/growth factor interactions. Handb. Exp. Pharmacol. 2012, 207:307-324.
99. Singh P., Schwarzbauer J.E. Fibronectin and stem cell differentiation - lessons from chondrogenesis. J. Cell Sci. 2012, 125(Pt 16):3703-3712.
100. Skjot-Arkil H., Schett G., Zhang C., Larsen D.V., Wang Y., Zheng Q., et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 2012, 30(3):371-379.
101. Skjot-Arkil H., Clausen R.E., Nguyen Q.H., Wang Y., Zheng Q., Martinez F.J., et al. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm. Med. 2012, 12(1):34.
102. Snowdon V.K., Fallowfield J.A. Models and mechanisms of fibrosis resolution. Alcohol. Clin. Exp. Res. 2011, 35(5):794-799.
103. Sohara N., Znoyko I., Levy M.T., Trojanowska M., Reuben A. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J. Hepatol. 2002, 37(2):214-221.
104. Sondergaard B.C., Wulf H., Henriksen K., Schaller S., Oestergaard S., Qvist P., et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006, 14(8):759-768.
105. Sun L., Louie M.C., Vannella K.M., Wilke C.A., LeVine A.M., Moore B.B., et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300(3):L341-L353.
106. Svensson L., Aszodi A., Reinholt F.P., Fassler R., Heinegard D., Oldberg A. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J. Biol. Chem. 1999, 274(14):9636-9647.
107. Sykes B., Ogilvie D., Wordsworth P., Wallis G., Mathew C., Beighton P., et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am. J. Hum. Genet. 1990, 46(2):293-307.
108. Takagi J., Erickson H.P., Springer T.A. C-terminal opening mimics 'inside-out' activation of integrin alpha5beta1. Nat. Struct. Biol. 2001, 8(5):412-416.
109. Taylor S.H., Al-Youha S., Van A.T., Lu Y., Wong J., McGrouther D.A., et al. Tendon is covered by a basement membrane epithelium that is required for cell retention and the prevention of adhesion formation. PLoS ONE 2011, 6(1):e16337.
110. Tromp G., Kuivaniemi H., Stolle C., Pope F.M., Prockop D.J. Single base mutation in the type III procollagen gene that converts the codon for glycine 883 to aspartate in a mild variant of Ehlers-Danlos syndrome IV. J. Biol. Chem. 1989, 264(32):19313-19317.
111. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol. Clin. Exp. Res. 1999, 23(5):911-916.
112. Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012, 31(1-2):295-321.
113. van de B.M., Groothuis G.M., Meijer D.K., Olinga P. Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol. In Vitro 2007, 21(4):545-557.
114. van der F.A., Sonnenberg A. Function and interactions of integrins. Cell Tissue Res. 2001, 305(3):285-298.
115. Van A.T., Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res. 2010, 339(1):167-188.
116. Van A.T., Bailey M.A., Schlotzer-Schrehardt U., Craigie E., Jackson I.J., Brownstein D.G., et al. Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume. Hum. Mol. Genet. 2010, 19(6):1119-1128.
117. Vassiliadis E., Veidal S.S., Simonsen H., Larsen D.V., Vainer B., Chen X., et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011, 16(5):426-433.
118. Vassiliadis E., Oliveira C., Alvares-da-Silva M.R., Zhang C., Carrilho F.J., Rabelo F., et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am. J. Transl. Res. 2012, 4(4):403-414.
119. Veidal S.S., Karsdal M.A., Nawrocki A., Larsen M.R., Dai Y., Zheng Q., et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 2011, 4:22.
120. Veidal S.S., Karsdal M.A., Vassiliadis E., Nawrocki A., Larsen M.R., Nguyen Q.H., et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS ONE 2011, 6(9):e24753.
121. Veidal S.S., Larsen D.V., Chen X., Sun S., Zheng Q., Bay-Jensen A.C., et al. MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin. Biochem. 2012, 45(7-8):541-546.
122. Wang Y.Z., Zhang P., Rice A.B., Bonner J.C. Regulation of interleukin-1beta-induced platelet-derived growth factor receptor-alpha expression in rat pulmonary myofibroblasts by p38 mitogen-activated protein kinase. J. Biol. Chem. 2000, 275(29):22550-22557.
123. Wang Y., Ma Y., Lu B., Xu E., Huang Q., Lai M. Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp. Biol. Med. (Maywood) 2007, 232(9):1152-1159.
124. Weil D., D'Alessio M., Ramirez F., Eyre D.R. Structural and functional characterization of a splicing mutation in the pro-alpha 2(I) collagen gene of an Ehlers-Danlos type VII patient. J. Biol. Chem. 1990, 265(26):16007-16011.
125. Wenstrup R.J., Florer J.B., Willing M.C., Giunta C., Steinmann B., Young F., et al. COL5A1 haploinsufficiency is a common molecular mechanism underlying the classical form of EDS. Am. J. Hum. Genet. 2000, 66(6):1766-1776.
126. Westra I.M., Pham B.T., Groothuis G.M., Olinga P. Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica 2013, 43(1):98-112.
127. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 2010, 207(3):535-552.
128. Woelfle J.V., Brenner R.E., Zabel B., Reichel H., Nelitz M. Schmid-type metaphyseal chondrodysplasia as the result of a collagen type X defect due to a novel COL10A1 nonsense mutation: a case report of a novel COL10A1 mutation. J. Orthop. Sci. 2011, 16(2):245-249.
129. Wong L., Yamasaki G., Johnson R.J., Friedman S.L. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J. Clin. Invest. 1994, 94(4):1563-1569.
130. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214(2):199-210.
131. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012, 18(7):1028-1040.
132. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998, 20(1):78-82.
133. Xu H., Bihan D., Chang F., Huang P.H., Farndale R.W., Leitinger B. Discoidin domain receptors promote alpha1beta1- and alpha2beta1-integrin mediated cell adhesion to collagen by enhancing integrin activation. PLoS ONE 2012, 7(12):e52209.
134. Young M.F., Bi Y., Ameye L., Chen X.D. Biglycan knockout mice: new models for musculoskeletal diseases. Glycoconj. J. 2002, 19(4-5):257-262.
135. Zaidel-Bar R., Itzkovitz S., Ma'ayan A., Iyengar R., Geiger B. Functional atlas of the integrin adhesome. Nat. Cell Biol. 2007, 9(8):858-867.